Updated:
iSpecimen Inc.
iSpecimen Inc. is a publicly traded biospecimen marketplace led by CEO Tracy Curley.
iSpecimen Inc.
iSpecimen Inc. was founded in 2013 to streamline procurement of human biospecimens for biomedical research. CEO Tracy Curley took the helm in 2021, succeeding Christopher Ianelli, who co-founded the firm. The company went public on the Nasdaq in 2021 under the ticker ISPC, offering shares at $10 per share and raising $41M in gross proceeds (per SEC filings). The firm's core business involves sourcing tissue, blood, urine, and other biospecimens from a network of hospitals, physician networks, and biobanks — then fulfilling orders from academic labs, biopharma companies, and clinical research organizations. iSpecimen operates a technology platform that matches research requirements with available specimens, with rejected specimens replaced in accordance with contractual terms. The firm states its network includes over 300 collection sites across North America and the UK. iSpecimen employs roughly 40 people based in its Burlington, Massachusetts headquarters. In recent years, the company has faced operational headwinds: its 2024 revenue was $6.8M with a net loss of $10.3M (per SEC filings), and its stock value fell below $1. During this period the firm implemented restructuring and shifted focus to higher-margin projects. A structural differentiator is iSpecimen's publicly traded commercial model — few biospecimen marketplaces are structured as standalone public entities. The company's ability to offer a transparent, compliance-driven marketplace contrasts with more opaque broker networks, though scaling remains constrained by recurring net losses.
General information
Firm type
other
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Burlington
Corporate office
Burlington, MA, United States
Principals
Tracy Curley
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at iSpecimen?
Tracy Curley serves as CEO, overseeing strategy and capital allocation. The board of directors includes independent members who guide major financial decisions. The firm files quarterly and annual reports with the SEC, which are publicly accessible (per SEC filings).
How does iSpecimen source its biospecimens?
iSpecimen partners with hospitals, physician practices, and biobanks to collect and supply de-identified biospecimens. The firm uses its platform to match researcher specifications from a network of over 300 collection sites across North America and the UK (per the firm's website). Collection is primarily direct from clinical settings, not via third-party brokers.
Is iSpecimen a biotech company or a technology marketplace?
iSpecimen is a technology-enabled marketplace that connects researchers to human biospecimens, not a biotech firm. It does not engage in drug development or therapeutic research but provides essential raw materials for such work. Its primary asset is its specimen network and procurement platform.
What investment stages does iSpecimen target?
iSpecimen is not an investment firm; it is an operating company that went public via IPO in 2021. It does not manage third-party capital or operate fund vehicles. Its economic model relies on per-specimen transaction fees and subscription-based access to its ordering platform.
Does iSpecimen serve academic or commercial researchers?
Both. iSpecimen lists academic research institutions, biopharma companies, diagnostics developers, and clinical research organizations as its customer base. The firm's platform supports a broad range of study types, from oncology to rare disease (per the firm's case studies).
What are iSpecimen's known financial challenges?
iSpecimen has not reported a net profit since its IPO, with 2024 revenue at $6.8M and a net loss of $10.3M (per SEC filings). The stock traded below $1 for an extended period, leading to a reverse stock split in 2024. The firm has cautioned that it may require additional capital to fund ongoing operations (per SEC risk disclosures).
How is iSpecimen structurally different from a biospecimen broker?
iSpecimen operates a transparent, compliance-focused platform with direct collection partnerships, rather than acting as a broker of existing inventories. Its public company structure subjects it to SEC oversight and quarterly earnings transparency, which is rare among specimen marketplaces. The firm also offers a proprietary fulfillment matching engine, which it contrasts with manual or phone-fax ordering methods.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: